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Executive summary 
This report presents annual screening data for the NHS Newborn Blood Spot (NBS) 
Screening Programme for the financial year 1 April 2017 to 31 March 2018.  
 
The aim of the report is to feedback performance against the national standards.  
 
Each standard has an acceptable and an achievable threshold. The acceptable 
threshold is the lowest level of performance which screening services are expected to 
attain, and the achievable threshold represents the level at which the screening service 
is likely to be running optimally.  
 
This year we have included recommendations for each standard based on the 
performance indicated by this year’s data. 
 
Child Health Records Departments (CHRDs) returned data for 196 out of 207 (94.7%) 
CCGs in England. Coverage measured at 17 days (CCG responsibility at birth) was 
reported to be 96.7% (above the 95% acceptable threshold). For movers in (see 
standard 1b for definition), coverage measured at 21 days was 90% in England. Whilst 
this was an improvement from last year’s performance (87.1%), it is still under the 
acceptable threshold of 95%. The screening programme needs to explore this further to 
understand barriers, impact and interventions that could help improve coverage of 
movers in.    
 
A total of 648,515 babies were screened in England (755,704 in UK). In England 84.1% 
of blood spot cards included the baby’s NHS number on a bar-coded label, compared to 
73.9% in 2016 to 2017. Although some regions are meeting the acceptable threshold 
(90%), no region is yet meeting the achievable threshold of 95%.  
 
In England, 94.3% of samples were received by laboratories within 3 working days of 
collection although this ranges by screening region from 84.5% to 97.5%. Northern 
Ireland achieved 98% and Wales 82.3% The UK mean 93.8%, was just below the 
acceptable threshold of 95%. 
 
In the UK, the reported number of screen positive babies for each condition were: 
 
• 329 for cystic fibrosis (CF) 
• 690 for congenital hypothyroidism (CHT) 
• 255 for sickle cell disease (SCD) 
• 113 for phenylketonuria (PKU) 
• 67 for medium chain actyl co-enzyme deficiency (MCADD) 
• 38 for the other 4 inherited metabolic diseases (IMDs) 
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Not all will have been confirmed to have the disorder in question. 
 
100% of MCADD, MSUD, IVA and GA1 screen positive babies were clinically referred 
within 3 working days of sample receipt. 
 
99.1% of PKU and 92.7% of CHT screen positive babies were clinically referred within 3 
working days of sample receipt. 
 
Blood spot quality continues to improve. Last year (2016 to 2017), England had an 
avoidable repeat rate of 2.9% and this year this has come down to 2.5%. Four out of the 
sixteen newborn screening laboratories reported avoidable repeat rate within the 2% 
acceptable threshold.  
 
The acceptable standard (95% by 28 days) for timeliness of first appointment for CF 
screen positive babies with 2 mutations, was met in Northern Ireland, whilst for England 
and Scotland, it accounted for 93.1% and 91.3% of babies respectively. Though there 
were 9 CF screen positive babies with 2 mutations identified by the Welsh screening 
programme, age at first appointment was not reported for these 9 babies. 
 
The acceptable standard (80% by 35 days) for timeliness of first appointment for CF 
screen positive babies with one or no mutations for England, Northern Ireland and 
Scotland, was 72.3%, 77.8% and 55.6% respectively. There was no age at first 
appointment reported for the 8 cases of CF screen positive babies with one or no 
mutations identified in Wales. 
 
Northern Ireland and Scotland met the acceptable standard (100% by 14 days) for 
timeliness of first appointment for CHT screen positive babies detected on first sample. 
Wales met the acceptable standard (100% by 21 days) for timeliness of first 
appointment for CHT screen positive babies detected on second sample.  
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Recommendations 
Standard 1a / KPI NB1: Coverage (CCG responsibility at birth) and Standard 1b / 
KPI NB4: Completeness of coverage (movers in) 
Recommendation 
Completeness can be improved in the Midlands and East and North Regions. 
Responsibility 
Commissioners of child health services. 
 
Standard 2: Timely identification of babies with a null or incomplete result on the 
CHIS 
Recommendation 
Completeness of these returns is particularly poor with 72.6% of CCGs returning data. 
All of those that did return data met at least the acceptable threshold. 
Responsibility 
Commissioners of child health services. 
 
Standard 3: Barcoded NHS number label is included on the blood spot card 
Recommendation 
Newborn screening laboratories should make efforts to report by maternity service as 
this is now a mandatory data field on the blood spot card. This will enable SQAS to 
monitor performance at maternity service level. This recommendation applies to 
standards 3 to 6. 
Responsibility 
Newborn screening laboratories. 
Recommendation 
Performance continues to rise. Support is still needed to make sure barcoded labels 
meet the recommended specification. 
Responsibility 
Providers of maternity services. 
 
Standard 4: Timely sample collection 
Recommendation 
Sample collection on day 5 should be recommended and reinforced to increase 
performance against this standard. Babies undergoing transfusion can have the sample 
collected on days 6 to 8, but they are not excluded from this standard. 
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Responsibility 
Providers of maternity services. 
 
Standard 5: Timely receipt of a sample in the newborn screening laboratory 
Recommendation 
Support of new standard measuring 3 days within collection needs to be supported and 
communicated to improve performance. 
Responsibility 
Providers of maternity services. 
 
Standard 6: Quality of the blood spot sample and Standard 7: Timely taking of a 
repeat blood spot sample 
No recommendation. 
 
Standard 9: Timely processing of CHT and IMD (excluding HCU) screen positive 
samples 
Recommendation 
Work to be done on how we measure receipt of sample. 
Responsibility 
Newborn screening laboratories 
 
Standard 11: Timely entry into clinical care: All conditions 
Recommendation 
Data for 2017-18 is particularly poor. 
Work must be done to improve the completeness of data for timely entry into care. 
Communication processes must be improved to address this gap in reporting. 
Responsibility 
Newborn screening laboratories 
 
Standard 12a: Timeliness of results to parents (CCG responsibility at birth) and 
Standard 12b: Timeliness of results to parents (movers in) 
Recommendation 
Completeness for standard 12 is poor. Work needs to be done in Midlands and East, 
North and South regions to improve completeness and data. The blood spot programme 
needs to work closely with SQAS in achieving a better data return and communicating 
the submission process widely. 
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Responsibility 
Commissioners of child health services 
 
Laboratory accreditation (standards 8 and 10) will be published by the United Kingdom 
Accreditation Service (UKAS). 
 
Acknowledgements 
The NHS Newborn Blood Spot (NBS) screening programme would like to thank all 
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Introduction 
This report presents screening data and performance analysis for the UK’s Newborn 
blood spot (NBS) screening programmes for the financial year 1 April 2017 to 31 March 
2018. The UK National Screening Committee (UK NSC) recommends that all babies in 
the UK are offered NBS screening for sickle cell disease (SCD), cystic fibrosis (CF), 
congenital hypothyroidism (CHT) and 6 inherited metabolic diseases (IMDs): 
phenylketonuria (PKU), medium-chain acyl-CoA dehydrogenase deficiency (MCADD), 
maple syrup urine disease (MSUD), isovaleric acidaemia (IVA), glutaric aciduria type 1 
(GA1) and homocystinuria (pyridoxine unresponsive) (HCU). The overall goal is to 
prevent ill health, disability and death through early diagnosis and effective intervention. 
 
One of the objectives of the NHS NBS screening programme is to set national 
standards (see Table 1 and Figure 1). National standards are important to support the 
delivery and quality assurance of the screening programme and are used by local 
commissioners and quality improvement groups. The aim of this report is to feedback 
performance against the national standards. Providers, commissioners and the 
Screening Quality Assurance Service (SQAS) are encouraged to review this report to 
identify areas for improvement locally. 
 
The newborn blood spot screening standards were revised in 2017 and this report 
reflects the new measures. 
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Table 1a: NBS standards (2017) Reporting focus and completeness 
Standard Reporting 
responsibility 
 
Reporting process Reporting focus Completeness 
2017/18  
(UK) 
Standard 1a: 
Completeness of 
coverage (CCG 
responsibility at 
birth). Collected as 
KPI NB1  
CHRD 
 
CCG KPI quarterly 
submission 
 
196/207 
(94.7%) 
Standard 1b: 
Completeness of 
coverage (movers 
in). Collected as KPI 
NB4  
CHRD CCG KPI quarterly 
submission 
 
196/207 
(94.7%) 
Standard 2: Timely 
identification of 
babies with a null or 
incomplete result 
recorded on the child 
health information 
system  
CHRD CCG Annual data 
submission direct 
to NBS 
programme 
170/207 
(82.1%) 
Standard 3: Barcoded 
NHS number is 
included on the blood 
spot card 
Newborn 
screening 
laboratory 
 
CHRD/CCG/Mater
nity unit (England), 
child health service 
(Northern Ireland),  
health board (Wales) 
or laboratory 
catchment area 
(Scotland) 
 
Annual data 
submission direct 
to NBS 
programme 
16/16 (100%) 
 
Standard 4: Timely 
sample collection  
Newborn 
screening 
laboratory 
 
CHRD/CCG/Mater
nity unit (England), 
child health service 
(Northern Ireland),  
health board (Wales) 
or laboratory 
catchment area 
(Scotland) 
 
 
 
 
Annual data 
submission direct 
to NBS 
programme 
16/16 (100%) 
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Standard Reporting 
responsibility 
 
Reporting process Reporting focus Completeness 
2017/18  
(UK) 
Standard 5: Timely 
receipt of a sample 
in the newborn 
screening laboratory  
Newborn 
screening 
laboratory 
 
CHRD/CCG/Mater
nity unit (England), 
child health service 
(Northern Ireland),  
health board (Wales) 
or laboratory 
catchment area 
(Scotland) 
Annual data 
submission direct 
to NBS 
programme 
16/16 (100%) 
 
Standard 6: Quality 
of the blood spot 
sample  
Newborn 
screening 
laboratory 
 
CHRD/CCG/Mater
nity unit (England), 
child health service 
(Northern Ireland),  
health board (Wales) 
or laboratory 
catchment area 
(Scotland) 
Annual data 
submission direct 
to NBS 
programme 
16/16 (100%) 
 
Standard 9: 
Timely 
processing of 
all CHT and 
IMD screen 
positive 
samples 
Newborn 
screening 
laboratory 
Annual data 
submission direct to 
NBS programme 
Newborn 
screening 
laboratory 
 
16/16 (100%) 
Standard 11: Timely 
entry into clinical 
care** 
 
 
Newborn 
screening 
laboratory 
Annual data 
submission direct to 
NBS programme 
Newborn 
screening 
labTE 
PKU- 61.1% 
MCADD- 76.2% 
IVA – 75% 
GA1- 100% 
HCU- 66.7% 
MSUD- 50.0% 
CHT- 93.0% 
CF- 66.8% 
Standard 12a: 
Timeliness of results 
to parents (CCG 
responsibility at birth) 
CCG CHRD 
 
Annual data 
submission direct 
to NBS 
programme  
165/207 (82.1%) 
Standard 12b: 
Timeliness of results 
to parents (movers in) 
CCG CHRD Annual data 
submission direct 
to NBS 
programme 
117/207* 
(56.5%) 
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*29 CCGs received the wrong template for reporting and therefore we do not have a complete dataset for Standard 12. Some 
CCGs have returned separate data for standard 12 and 12b and some returned data as a whole for the previous version of the 
standard, which combined both parts a and b. 
 
**Completeness of appointment data excludes babies clinically diagnosed and is shown as percentage of all screen positive 
babies that have an age at appointment reported. 
 
Standard 7 a, b and c (timely taking of a second blood spot sample) is not currently 
collected. Standard 8 (UKAS screening) and standard 10 (UKAS diagnosis) are part of 
UKAS accreditation and not included in this report. 
 
Data are presented by financial year (1 April to 31 March) unless stated otherwise. The 
year ‘2017 to 2018’ for example, refers to the financial year 1 April 2017 to 31 March 
2018.  
 
Table1b: Table of how newborn screening laboratories report standards data by: 
Laboratory Report standards data by: 
Bristol Maternity Services 
Cambridge Maternity Services 
Great Ormond Street Hospital (GOSH) Maternity Services 
Leeds  Maternity Services 
Liverpool CCG 
Manchester Maternity Services 
Newcastle CCG 
Oxford CHRD 
Portsmouth CHRD 
SE Thames Maternity Services 
Sheffield CHRD 
SW Thames Maternity Services 
West Midlands CHRD 
Northern Ireland HSC Trust 
Scotland Country 
Wales Health Board 
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Figure 1: NBS standards mapped to a generic screening pathway 
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Analysis of screening performance 
Overview of UK national screening figures 
Number of babies tested and number of screen positive results. 
 
Table 2: Number of UK babies tested and number of screen positive results for SCD, CF 
and CHT 1 April 2017 to 31 March 2018 
Laboratory SCD CF CHT 
Number 
tested 
Number of 
screen 
positives 
Number 
tested 
Number of 
screen 
positives 
Number 
tested 
Number of 
screen 
positives 
Bristol 39,345 4 39,345 22 39,345 43 
Cambridge 27,008 3 27,008 14 27,008 18 
GOSH 121,488 79 121,488 34 121,488 127 
Leeds 41,174 11 41,293 19 41,293 41 
Liverpool 28,230 3 28,191 11 28,191 34 
Manchester 53,098 15 52,992 26 53,335 49 
Newcastle 31,562 5 31,075 17 31,075 36 
Oxford 27,337 9 28,036 10 28,036 19 
Portsmouth 36,834 4 34,578 14 35,032 37 
SE Thames 57,919 49 55,711 19 55,990 40 
Sheffield 68,612 15 67,705 30 68,119 68 
SW Thames 51,143 35 51,050 14 51,050 38 
West Midlands 67,924 21 68,553 32 68,553 63 
England  651,674 253 647025 262 648,515 613 
Northern Ireland 22,923 0 22,833 18 22,922 21 
Scotland  52,552 2 52,552 32 52,552 37 
Wales 31,715 2 31,653 17 31,715 19 
UK total 758,864 257 754,063 329 755,704 690 
Data source: Newborn screening laboratories 
 
We would normally expect to see a lower number of babies tested for CF, than for the 
other conditions, as the screening test is not reliable, and therefore not undertaken, in 
babies over 8 weeks of age. This will apply to some movers in. This is reflected in data 
from 6 of the laboratories. 
 
Note that a significant proportion of screen positive results will not be confirmed cases. 
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Table 3: Number of UK babies tested and number of screen positive results for IMDs  
1 April 2017 to 31 March 2018 
Laboratory 
PKU MCADD MSUD, IVA, GA1, HCU 
Number 
tested 
Number of 
screen 
positives 
Number 
tested 
Number of 
screen 
positives 
Number 
tested 
Number of 
screen 
positives 
Bristol 39,345 2 39,345 3 39,345 1 
Cambridge 27,008 4 27,008 5 27,008 2 
GOSH 121,488 9 121,488 10 121,488 7 
Leeds 41,293 7 41,293 5 41,293 2 
Liverpool 28,191 3 28,191 3 28,191 0 
Manchester 53,335 5 53,335 7 53,335 5 
Newcastle 31,075 7 31,075 2 31,075 0 
Oxford 28,036 3 28,036 2 28,036 1 
Portsmouth 35,032 7 35,032 2 35,032 0 
SE Thames 55990 15 55,990 3 55,990 2 
Sheffield 68,119 13 68,119 5 68,119 4 
SW Thames 51,050 6 51,050 4 51,050 4 
West Midlands 68,553 5 68,553 5 68,553 5 
England  648,515 86 648515 56 648,515 33 
Northern Ireland 22,922 7 22,922 3 n/a* n/a 
Scotland  52,552 16 52,552 4 52,552 5 
Wales 31,715 4 31,715 4 31,715 0 
UK total 755,704 113 755704 67 755,704 38 
Data source: Newborn screening laboratories 
*Northern Ireland do not screen for MSUD, IVA, GA1 or HCU. 
 
Figure 2: Screen positive rate (per 10,000) for babies screened for PKU, CHT, CF, 
MCADD and SCD 2005 to 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
Data for SCD includes England only prior to 2015 to 2016. 
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It can be observed that the screen positive rate for CHT is rising and for SCD is falling. 
There is no evidence to explain these trends, there may be several confounding factors.  
The TSH cut off levels for CHT borderline samples is not the same across the country 
and therefore those laboratories using a lower cut off are reporting higher incidence of 
screen positive cases. When all laboratories use the same cut off level, incidence 
should stabilise, and a true screen positive rate can be measured. 
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Standard 1a / KPI NB1: Coverage (CCG 
responsibility at birth)  
Description  
The proportion of babies registered within the CCG both at birth and on the last day of 
the reporting period who are eligible for NBS screening and have a not suspected, 
suspected or carrier result recorded on the CHIS for each of the 9 conditions at less 
than or equal to 17 days of age. 
 
Acceptable threshold 
≥ 95.0% of eligible babies have a result for each of the 9 conditions recorded on the 
CHIS at less than or equal to 17 days of age.  
 
Achievable threshold  
≥ 99.0% of eligible babies have a result for the IMDs recorded on the CHIS at less than 
or equal to 17 days of age.  
 
Achievable threshold  
≥ 98.0% of eligible babies have a result for CF, CHT and SCD recorded on the CHIS at 
less than or equal to 17 days of age. 
 
This standard is a Key Performance Indicator (KPI). PKU is used as a proxy for all 
conditions screened for, through newborn blood spot screening. More information on 
KPI definitions can be found on Gov.UK. The Newborn Blood Spot Failsafe Solution 
(NBSFS) now records ‘screening complete’ status which will enable coverage reporting 
for each condition in the future. Data on standards 1a and1b are collected as key 
performance indicators (KPIs); compiled from 4 quarterly returns. In the annual KPI 
data, providers are excluded where data has not been submitted for all 4 quarters in 
that year. 
 
Table 4: Coverage of newborn screening measured against PKU: CCG responsibility at 
birth (born and registered population), 1 April 2017 to 31 March 2018: England and 
Northern Ireland 
Region Eligible babies Tested babies  Coverage (%)  
England 566,557 547,645 96.7 
London 120,648 115,258 95.5 
Midlands & East 150,642 145,850 96.8 
North 152,468 147,623 96.8 
South 142,799 138,914 97.3 
Northern Ireland  22,568 22,362 99.0 
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Table 5: Completeness of data for coverage, England and Northern Ireland, 1 April 2017 
to 31 March 2018 
Completeness Number of returns No. of 'No returns' % Complete 
England 196 11 94.7 
London 32 0 100.0 
Midlands & East 55 6 90.2 
North 59 5 92.2 
South 50 0 100.0 
Northern Ireland  1 0 100.0 
Data source: national quarterly [annual aggregate] KPI data collection 
 
Figure 3: Coverage of newborn screening measured using PKU: CCG responsibility at 
birth (born and registered population, measured at 17 days), 2010 to 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: national quarterly [annual aggregate] KPI data and annual CHRD data collection received from Northern Ireland. 
Please note the y axis does not start at 0% 
 
The achievable threshold was lowered from 99.9% to 99.0% in 2017 and subsequently 
this threshold was met by Northern Ireland in 2017-18. Performance against the 
standard continues to improve overall in England with all regions meeting the 
acceptable threshold. Completeness can be improved in the Midlands and East and 
North Regions. 
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Standard 1b / KPI NB4: Completeness of 
coverage (movers in) 
Description  
The proportion of all babies eligible for newborn blood spot (NBS) screening who have 
both: 
 
• changed responsible clinical commissioning group (CCG), or have moved in from 
another UK country or abroad, in the reporting period 
• a conclusive result for phenylketonuria (PKU) recorded on the child health 
information service system (CHISS) at less than or equal to 21 calendar days of 
notifying the child health department of movement in. 
 
Acceptable threshold   
≥ 95.0% of eligible babies have a result for each of the 9 conditions (or 5 conditions if 
not eligible for expanded screening) recorded on the CHIS at less than or equal to 21 
calendar days of notifying the CHRD of movement in.  
 
Achievable threshold   
≥ 99.0% of eligible babies have a result for the IMDs recorded on the CHIS at less than 
or equal to 21 calendar days of notifying the CHRD of movement in.  
 
Table 6. KPI NB-4. Coverage of newborn screening measured using PKU: movers in, 1 
April 2017 to 31 March 2018: England 
Regional summary Eligible babies Tested babies Coverage (%)  
England 42,834 38,550 90.0 
London 10,160 8,981 88.4 
Midlands & East 11,701 10,517 89.9 
North 10,897 9,935 91.2 
South 10,076 9,117 90.5 
 
Table 7: Completeness of data for coverage, movers in, England and Northern Ireland, 1 
April 2017 to 31 March 2018 
Completeness Number of returns No. of 'No returns' % Complete 
England 196 11 94.7 
London 32 0 100.0 
Midlands & East 55 6 90.2 
North 59 5 92.2 
South 50 0 100.0 
Data source: national quarterly [annual aggregate] KPI data collection 
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From 2010 to 2014, data was collected to measure coverage for movers in without 
applying an effective timeframe. Standard 1b introduces an effective timeframe of 21 
calendar days; 2014 to 2018 data are presented with the timeframe in addition to year-
on-year data without the timeframe. The introduction of the timeframe effected 
performance as seen in 2015/16 data but since this adjustment performance has risen 
yearly to 90%. Northern Ireland did not return data for babies tested within the 
timeframe for 2017 to 2018. 
 
Figure 4: Completeness of coverage for PKU (movers in) 2010 to 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: national quarterly [annual aggregate] KPI data collection 
 
*Achievable threshold changed from 99.9% to 99% in 2017. 
Please note the y axis does not start at 0%. 
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CHRD process data 
 
Table 8: Receipt, recording and despatch of results by CHRDs 1 April 2017 to 31 March 
2018 (reported per CCG) 
Number of CHRDs that: 
Region / 
Country 
receive 
results 
by hard 
copy 
receive 
results by 
email 
receive 
results by 
electronic 
messaging 
receive 
results 
with status 
codes 
record 
results 
using status 
codes 
send letters 
directly to 
parents 
when 04* is 
reported on 
all 
conditions 
total 
num
ber 
of 
CCG
s**  
n % N % n % n % n % n % n 
London 0 0.0 32 100 0 0.0 32 100 32 100 32 100 32 
Midlands 
and East 
4 7.8 36 70.6 15 29.4 51 100 51 100 46 90.2 51 
North 27 57.4 34 72.3 20 42.6 47 100 44 93.6 32 68.1 47 
South 30 65.2 32 69.6 17 37.0 46 100 46 100 46 100 46 
England  61 34.7 134 76.1 52 29.5 176 100 173 98.3 156 88.6 176 
Northern 
Ireland† 
1 100 0 0.0 1 100.0 1 100 1 100 0 0.0 1 
Data source: CHRDs 
*Status code 04; condition screened for not suspected 
**For which a return was received. For some CCGs more than one return was received 
†Northern Ireland does not issue letters regarding results to parents. Results go to parents via the health visitor and a second 
set of results are inserted in the PCHR 
 
The data highlights the multiplicity of methods by CHRDs receive results.  
 
Figure 5: Percentage of CHRDs who receive results by hard copy, email and electronic 
messaging 2017 to 2018 
 
Data source: CHRDs 
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Standard 2: Timely identification of babies 
with a null or incomplete result on the CHIS  
Description 
The NBS programme relies on regular checks of the CHIS to identify babies with a null 
or incomplete result within an effective timeframe. Reports are produced to identify 
these babies and action is taken to follow them up, according to local protocols. 
 
Acceptable threshold 
CHRD performs regular checks (ideally daily, minimum weekly) to identify babies ≥ 17 
days and ≤ 364 days with a null or incomplete result. 
 
Achievable threshold  
CHRD performs regular checks (ideally daily, minimum weekly) to identify babies ≥ 14 
days and ≤ 364 days with a null or incomplete result. 
 
Table 9: Number and percentage of CHRDs that search for missing results at 17 days, 14 
days, 1 April 2017 to 31 March 2018 
Completeness Number of returns No. of 'No returns' % Complete 
England 196 11 94.7 
London 32 0 100.0 
Midlands & East 55 6 90.2 
North 59 5 92.2 
South 50 0 100.0 
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Figure 6: Number of CHRDs that search for missing results at 17 days, 14 days, 1 April 
2017 to 31 March 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completeness of these returns is particularly poor with 72.6% of CCGs returning data. 
All of those that did return data met at least the acceptable threshold. 
 
The Newborn Blood Spot Failsafe Solution (NBSFS) alerts maternity sites and CHRDs 
of babies born in England who have not been offered screening. It is unclear whether 
CHRDs checking NBSFS are reporting this as their process for identifying missing 
results. NBSFS does not receive notification of babies born outside England, so regular 
checks of the CHIS are still required. 
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Standard 3: Barcoded NHS number label is 
included on the blood spot card 
Description 
Use of the NHS number on the baby’s blood spot card is mandatory in England. Use of 
a barcoded NHS number label will reduce the risk of an inaccurate NHS number on the 
blood spot card which would require a repeat sample to be taken. 
 
Acceptable threshold 
 ≥ 90.0% of blood spot cards are received by the laboratory with the baby’s NHS 
number on a barcoded label. 
 
Achievable threshold 
≥ 95.0% of blood spot cards are received by the laboratory with the baby’s NHS number 
on a barcoded label. 
 
Table 10: Use of the bar-coded label 1 April 2017 to 31 March 2018, England 
Regional summary Denominator Numerator Performance (%) 
Bristol 37,950 34,780 91.6% 
Cambridge 29,651 27,400 92.4% 
GOSH 125,483 104,754 83.5% 
Leeds  43,516 32,033 73.6% 
Liverpool 29,844 23,253 77.9% 
Manchester 53,757 45,106 83.9% 
Newcastle 33,150 27,175 82.0% 
Oxford  29,699 22,607 76.1% 
Portsmouth 32,884 26,975 82.0% 
SE Thames 57,979 51,273 88.4% 
Sheffield 72,059 62,183 86.3% 
SW Thames 52,880 47,240 89.3% 
West Midlands 71,872 59,597 82.9% 
England 670,724 564,376 84.1% 
Data source: Newborn screening laboratories 
*Use of Health and Care number (equivalent to NHS number) in Northern Ireland is not mandatory 
‘Out of area’ samples have been removed from this data. 
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Figure 7: Percentage of blood spot cards including a bar-coded NHS number (or UK 
equivalent) 2010 to 2018, England 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
 
Both Wales and Scotland do not currently use bar coded label, but both reported 98.8% 
of samples received in the lab were complete with NHS number. 
 
The increase in performance in 2017/18 can be attributed to bar coded label becoming 
a standard in 2017. Previously, NHS number was the acceptable measure, bar coded 
label was the achievable measure. 
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Standard 4: Timely sample collection   
Description  
It is essential to take the blood spot sample promptly to give each screen positive baby 
the best possible chance of receiving early treatment. The health professional 
responsible for taking the blood sample should adhere to the guidelines for newborn 
blood spot sampling to ensure a valid sample is taken. 
 
Acceptable threshold 
Equal to or greater than 90% of first samples taken on day 5. 
 
Achievable threshold 
Equal to or greater than 95% of first samples taken on day 5. 
 
Table 11: Day of first sample collection 1 April 2017 to 31 March 2018* 
Laboratory Total number of 
samples 
Number of samples 
taken on day 5 
% of samples 
taken on day 
5 
Bristol 35,139 29,482 83.9% 
Cambridge 26,906 24,892 92.5% 
GOSH 123,507 92,812 75.1% 
Leeds 40,895 33,100 80.9% 
Liverpool 28,534 24,895 87.2% 
Manchester 50,394 43,676 86.7% 
Newcastle 31,075 26,758 86.1% 
Oxford  25,725 22,406 87.1% 
Portsmouth 31,660 28,629 90.4% 
SE Thames 55,917 46,915 83.9% 
Sheffield 67,727 55,193 81.5% 
SW Thames 50,973 43,359 85.1% 
West Midlands 67,282 61,727 91.7% 
England total 635,734 533,844 84.0% 
Northern Ireland  22,953 21,780 94.9% 
Scotland† 52,494 34,850 66.4% 
Wales 31,603 24,674 78.1% 
UK Total 742,784 615,148 82.8% 
Data source: Newborn screening laboratories 
*For the purposes of this standard, day of birth is taken as day 0. Pre-transfusion samples are excluded from the denominator 
and numerator. 
†Scotland accept samples to be taken on or before day 4 without asking for repeat. In 2017 to 2018 21.5% of samples were 
received on or before day 4. If these are included, the percentage (%) will be higher. 
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Figure 8: Percentage of samples taken day 5-8, 2015 to 2017 and on day 5, 2015 to 2018 
 
Data source: Newborn screening laboratories 
 
Prior to 2017, the standard measured sample collection day 5 to 8. The number of blood 
spots taken on day 5 has increased in all countries but has yet to meet the acceptable 
threshold in England, Scotland or Wales. 
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Figure 9: Percentage of samples taken before, on and after day 5, 2017 to 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
Scotland do not measure day 4 as too early for sample collection and therefore have a large proportion of samples taken on 
day 4. 
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Standard 5: Timely receipt of a sample in 
the newborn screening laboratory 
Description 
All samples must arrive within the screening laboratory as soon as possible after the 
sample has been taken. This enables the laboratory to analyse the sample at the 
earliest opportunity and also reduces the risk of sample deterioration due to prolonged 
despatch. 
 
Acceptable threshold 
≥ 95.0% of all samples received less than or equal to 3 working days of sample 
collection. 
 
Achievable threshold 
≥ 99.0% of all samples received less than or equal to 3 working days of sample 
collection. 
 
Table 12: Number of working days taken to receive sample 1 April 2017 to 31 March 2018 
Laboratory Samples received 
within 3 working days 
n % 
Bristol 32,082 84.5% 
Cambridge 26,697 96.5% 
GOSH 118,258 94.5% 
Leeds 39,928 91.8% 
Liverpool 29,220 97.9% 
Manchester 51,350 97.6% 
Newcastle 31,061 93.9% 
Oxford 25,427 85.6% 
Portsmouth 31,195 95.4% 
SE Thames 55,446 95.6% 
Sheffield 66,183 92.5% 
SW Thames 51,745 97.9% 
West Midlands 70,022 97.5% 
England total 628,614 94.3% 
Northern Ireland 24,712 98.0% 
Scotland 49,113 93.6% 
Wales  29,036 82.3% 
UK total 731,475 93.8% 
Data source: Newborn screening laboratories 
‘Out of area’ samples have been removed from this data. 
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Figure 10: Number of samples received in 4 working days, 2013 to 2017 and 3 working 
days of sample being taken, 1 April 2017 to 31 March 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
Please note the Y axis does not begin at zero. 
 
In April 2017 the standard was changed from measuring samples received in the lab 
within 3 (achievable threshold) and 4 (acceptable threshold) to measuring all samples 
received within 3 working days of sample collection. 
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Standard 6: Quality of the blood spot sample 
Description 
Good quality blood spot samples are vital to ensure that babies with rare but serious 
conditions are identified and treated early.  
  
Good quality samples should be obtained first time to prevent the need for avoidable 
repeats. Avoidable repeat samples can cause anxiety for parents, distress to babies 
and delays in the screening process. They are also a waste of resources. 
 
A good quality blood spot sample is one that:  
  
• is taken at the right time  
• has all data fields completed to enable identification of the baby, analysis and 
reporting of results   
• contains sufficient blood to perform all tests (each circle filled and evenly saturated 
by a single drop of blood that soaks through to the back of the blood spot card  
• is not contaminated  
• arrives in the laboratory in a timely manner 
 
Acceptable threshold 
Avoidable repeat rate is ≤ 2.0%. 
 
Achievable threshold 
Avoidable repeat rate is ≤ 1.0%. 
 
New consensus guidelines on quality blood spot were introduced in April 2015 following 
which the percentage of avoidable repeats predictably rose. They have since improved. 
Four out of the sixteen newborn screening laboratories reported avoidable repeat rate 
within the 2% acceptable threshold. 
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Figure 11: Avoidable repeat request rates for UK countries 2012 to 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13: Avoidable repeat request rates 1 April 2017 to 31 March 2018 
Laboratory First samples 
received/babies 
tested 
Repeat (second or subsequent) samples requested 
by the laboratory because the previous sample 
was: 
Avoidable 
repeat 
request 
rate taken when the 
baby was too 
young* 
insufficient unsuitable 
n n % n % n % % 
Bristol 35,138 67 0.19% 265 0.75% 599 1.7% 2.65% 
Cambridge 26,985 23 0.09% 159 0.59% 231 0.9% 1.53% 
GOSH 123,598 223 0.18% 725 0.59% 2415 2.0% 2.72% 
Leeds 41,293 198 0.48% 914 2.21% 594 1.4% 4.13% 
Liverpool 29,844 50 0.17% 520 1.74% 83 0.3% 2.19% 
Manchester 53,335 90 0.17% 621 1.16% 606 1.1% 2.47% 
Newcastle 31,075 57 0.18% 372 1.20% 326 1.0% 2.43% 
Oxford 28,036 54 0.19% 170 0.61% 302 1.1% 1.88% 
Portsmouth 31,836 81 0.25% 188 0.59% 320 1.0% 1.85% 
SE Thames 55,917 150 0.27% 322 0.58% 719 1.3% 2.13% 
Sheffield 68,217 105 0.15% 740 1.08% 1262 1.7% 2.92% 
SW Thames 51,005 91 0.18% 279 0.55% 856 1.7% 2.40% 
West Midlands 67,333 85 0.13% 1110 1.65% 155 0.2% 2.00% 
England total 643,612 1274 0.20% 6385 0.99% 8468 1.3% 2.51% 
Northern Ireland 23,072 104 0.45% 857 3.71% 0 0.0% 4.17% 
Scotland 52552 69 0.13% 946 1.80% 1040 2.0% 3.91% 
Wales  31603 62 0.20% 573 1.81% 884 2.8% 4.81% 
UK total 750839 1509 0.20% 8761 1.17% 10392 1.4% 2.75% 
Data source: Newborn screening laboratories  
*Not all English laboratories ask for a repeat when the first sample was taken on or before day 4. 
0%
1%
2%
3%
4%
5%
6%
7%
8%
2012-13 2013-14 2014-15 2015-16 2016-17 2017-18
%
 o
f 
a
v
o
id
a
b
le
 r
e
p
e
a
ts
England Acceptable threshold  2% Achievable threshold 0.5%
Northern Ireland Scotland Wales
C
h
an
ge
 o
f
ac
h
ie
va
b
le
 t
h
re
sh
o
ld
 in
 A
p
ri
l 2
0
1
7
Data collection and performance analysis report: Newborn blood spot screening in the UK 2017 to 2018 
 
33 
New consensus guidelines on quality blood spot were introduced in April 2015 following 
which the percentage of avoidable repeats predictably rose. They have since improved. 
Three out of the sixteen newborn screening laboratories reported avoidable repeat rate 
within the 2% acceptable threshold.  
 
Figure 12: Breakdown of unsuitable samples for UK 1 April 2017 to 31 March 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 shows that the majority of unsuitable samples are due to insufficient blood. 
However, over 5,000 babies required a repeat blood spot test to be taken due to 
missing or incorrect information being recorded on the card. This is unacceptable and 
further efforts must be made to eradicate these avoidable errors. See programme 
resources including a new eLearning module ‘Newborn blood spot sample’ accessible 
here. 
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Standard 7: Timely taking of a repeat blood 
spot sample 
Description 
Timely taking of a second blood spot sample is vital to maximise accuracy of the 
screening test and ensure that clinical referral and treatment targets are met. 
 
7a: CF  
Acceptable threshold 
≥ 95% of second blood spot samples taken on day 21 to day 24 (this allows for day 21 
to fall on a weekend when a special visit is not warranted). 
Achievable threshold 
≥ 70% of second blood spot samples taken on day 21. 
 
7b: CHT borderline 
Acceptable threshold 
≥ 95.0% of second blood spot samples taken as defined. 
Achievable threshold  
≥ 99.0% of second blood spot samples taken as defined. 
 
7c: CHT preterm  
Acceptable threshold  
≥ 95% of second blood spot samples taken as defined. 
Achievable threshold 
≥ 70% of second blood spot samples taken as defined. 
 
Laboratory information management systems do not currently support collection of data 
for this standard. 
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Standard 9: Timely processing of CHT and 
IMD (excluding HCU) screen positive 
samples  
Description 
Timely processing of all screen positive samples is vital to ensure that health benefits 
are achieved by reducing morbidity/mortality. 
 
To facilitate high quality and timely intervention in those who wish to participate. 
 
The proportion of CHT and IMD (excluding HCU) screen positive results available and 
clinical referral initiated within 3 working days of sample receipt by the screening 
laboratory. 
 
Acceptable threshold 
100% of babies with a positive screening result (excluding HCU) have a clinical referral 
initiated within 3 working days of sample receipt by screening laboratory. 
 
Figure 13: Percentage of babies with a CHT and IMD (excluding HCU) positive screening 
result referred within 3 working days, UK, 1 April 2017 to 31 March 2018 
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Standard 11: Timely entry into clinical care 
Sickle cell disease 
Newborn screening for sickle cell disease (SCD) saw approximately 650,000 newborn 
babies screened for SCD in England in 2017 to 2018 and approximately 758,000 for the 
whole of UK. Of those screened in England, 253 babies were identified with significant 
conditions* (0.39 per 1000 screened) and approximately 8,150 babies were identified as 
carriers* (12.53 per 1000 screened). 
 
There has been a decline in the rate of babies screening positive for significant SCD 
conditions in England, which has been driven by decreases in London, particularly in 
the years up to 2015 to 2016. Over the last 3 years the rates in London have stabilised, 
and the rates in the rest of England remain steady. The rates of babies with carrier 
results have also decreased in England in the years up to 2017 to 2018, and this is 
again due to decreases seen in London. 
 
While beta thalassaemia is not currently screened for in newborn screening, F-only 
cases are picked up as a by-product of screening for sickle cell disease. These are 
likely to be beta thalassaemia major cases and require follow-up. In 1 April 2017 to 31 
March 2018 there were 25 F-only cases in England. 
 
Rates of declines for newborn screening for SCD continue to rise and are now at 
approximately 2.8 per 1,000 babies screened. The reason for this increase is not clear, 
but it may be due to improved reporting of declines or declines for mover-in babies who 
are older babies and may have been tested elsewhere. Although rates of declines are 
not collected for the other conditions screened, this pattern of declines is unlikely to be 
confined to just screening for SCD. 
 
The SCT programme has 2 screening standards relating to newborn screening for SCD. 
Screening standard 8 (SCT-S08) collects the proportion of parents receiving newborn 
screen positive results at less than or equal to 28 days of age. In 2017 to 2018 the 
England performance for this standard was 65.1%, which is below the acceptable 
threshold of 90%. Screening standard 9 (SCT-S09) collects the proportion of newborn 
infants with a positive screening result who are seen at a paediatric clinic or discharged 
for insignificant results by 90 days of age. Performance for this standard in England in 
2017 to 2018 was 82.7%, which is below the acceptable threshold of 90%. 
 
* Significant conditions comprise FS, FSC, FS-other and FE results. Carrier results comprise FAS, FAC, FAD, FAE and other 
haemoglobin variants. 
 
Information provided by the NHS Sickle Cell and Thalassaemia Screening Programme. 
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CF – screen positive babies with 2 cystic fibrosis transmembrane conductance 
regulator (CFTR) mutations 
Description 
A baby in whom CF is suspected should have their first clinical appointment by 28 days 
of age. 
 
Acceptable threshold  
≥ 95% of babies attend first clinical appointment by 28 days of age.  
 
Achievable threshold 
≥ 100% of babies attend first clinical appointment by 28 days of age. 
 
Table 14: Timeliness of appointment and outcome for CF screen positive babies with 2  
mutations 1 April 2017 to 31 March 2018 
  England Northern 
Ireland 
Scotland Wales 
Number of CF screen positive babies with 
2 mutations 
160 8 20 9 
Number diagnosed before screening 
(excluded from following age data) 
31 1 3 0 
Number of babies with age at first 
appointment reported 
102 7 16 0 
Number seen ≤ 28 days  95 
(93.1%) 
7 13 
(81.3%) 
N/A 
(% of known data) 
All babies mean age at first appointment 22 days 22 24 N/A 
All babies median age at first appointment 21 days 22 23 N/A 
Age range at first appointment 11-39  
days 
21-23  
days 
11-46 
days 
N/A 
Number of babies with age at first 
appointment not reported 
27 0 1 9 
Outcome (out of ALL babies screened positive with 2 mutations. Includes number diagnosed 
before screening) 
Confirmed 127 8 18 9 
CF SPID 10 0 1 0 
Excluded 0 0 0 0 
Not reported 23 0 1 0 
Data source: Newborn screening laboratories 
Note that different screening and diagnostic protocols are followed in the UK. 
 
Figures 14 and 15 show the various pathway points of each screen positive baby. Each 
vertical row of points represents one baby. 
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Figure 14: age in days of screen positive babies with 2 mutations at time of first sample, 
receipt in laboratory, referral and assessment, UK 
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CF – screen positive babies with one or no mutations 
 
Description 
A baby in whom CF is suspected should have their first clinical appointment by 35 days 
of age. 
 
Acceptable threshold  
80% of babies attend first clinical appointment by 35 days of age. 
 
Achievable threshold  
100% of babies attend first clinical appointment by 35 days of age. 
 
Table 15: Timeliness of appointment and outcome for CF screen positive babies with 
one or no mutations 1 April 2017 to 31 March 2018 
  England Northern 
Ireland 
Scotland Wales* 
Number of CF screen positive babies with 
one or no mutations 
102 10 9 8 
Number diagnosed before screening 
(excluded from following age data) 
4 0 0 0 
Number of babies with age at first 
appointment reported 
65 9 9 0 
Number seen ≤ 35 days (% of known data) 47 (72.3%) 7 (77.8%) 5 (55.6%) 0 
All babies mean age at first appointment 36 31 35 0 
All babies median age at first appointment 31 29 32 0 
Age range at first appointment 24-104 days 26-39 
days 
26-57 
days 
0 
Number of babies with age at first 
appointment not reported 
33 1 (R.I.P) 0 8 
Outcome (out of ALL babies screened positive with 1 or 0 mutations. Includes number diagnosed 
before screening) 
Confirmed 25 3 1 0 
CF SPID 2 0 0 0 
Excluded 31 6 7 8 
Baby died  1 1 0 0 
Not reported 36 0 1 0 
Carrier 7 0 0 0 
Other       0 
Data source: Newborn screening laboratories 
*Wales data does not include 0 mutations. 
Data collection and performance analysis report: Newborn blood spot screening in the UK 2017 to 2018 
 
40 
Figure 15: Age in days of babies screened positive for CF with one or no mutations, at 
time of first sample, second sample, referral and assessment, UK  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
 
Figure 16: CF screen positive babies comparing 2 with one or no mutations 1 April 2017 
to 31 March 2018, UK: Age in days at time of first appointment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
The X axis stops at 54 days. Eight babies received an appointment after this age. 
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CF screen positive data 2007 to 2018 
Table 16: CF screen positive data 2007 to 2018 
Laboratory Rate of CF screen positives 2007 to 2018 
Rate per 10,000 
Bristol 5.84 
Cambridge 4.30 
GOSH 2.75 
Leeds 4.11 
Liverpool 5.50 
Manchester 3.75 
Newcastle 4.64 
Oxford 2.77 
Portsmouth 3.97 
SE Thames 3.67 
Sheffield 4.46 
SW Thames 3.21 
West Midlands 3.86 
England total 3.88 
Northern Ireland 6.23 
Scotland 5.55 
Wales 5.77 
UK total 4.14 
Data source: Newborn screening laboratories 
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CHT – screen positive babies detected on first sample (not including preterm 
babies) 
Description 
A baby in whom CHT is suspected on the first sample should attend their first clinical 
appointment by 14 days of age.  
 
Acceptable level 
100% by 14 days of age.  
 
Table 17: Timeliness of appointment and treatment outcome for CHT screen positive 
babies detected on first sample 1 April 2017 to 31 March 2018  
England Northern 
Ireland 
Scotland Wales 
Number of CHT screen 
positive babies detected 
on first sample 
326 11 24 14 
Number diagnosed before 
screening (excluded from 
following age data) 
11 0 0 0 
Number of babies with age 
at first appointment 
reported 
296 11 24 13 
Number seen ≤ 14 days 
standard (% of known 
data) 
265 (89.5%) 11 (100%) 24 (100%) 11 (84.6%) 
All babies mean age at first 
appointment 
13 days 10 days 11 days 12 days 
All babies median age at 
first appointment 
11 days 10 days 11 days 12 days 
Age range at first 
appointment 
6-376 days 8-11 days 7-14 days 09-15 days 
Number of babies with age 
at first appointment not 
reported 
19 0 0 1 
Inpatient  2 0 0  0  
Other* 0 0 0   1 
Data source: Newborn screening laboratories 
*One baby indicated as “DECLINE; mother refused to bring child, GP had to treat at home”. 
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Figure 17: Treatment outcome for CHT screen positive babies, UK, ‘Are babies treated 
with Thyroxine?’  
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CHT – screen positive babies detected on second sample (not including preterm 
babies) 
Description 
A baby in whom CHT is suspected on a repeat blood spot sample that follows a 
borderline TSH should have their first clinical appointment by 21 days.  
 
Acceptable threshold 
100% by 21 days of age.  
 
Table 18: Timeliness of appointment and treatment outcome for CHT screen positive 
babies detected on second sample 1 April 2017 to 31 March 2018  
England Northern 
Ireland 
Scotland Wales 
Number of CHT screen positive babies 
detected on second sample 
241 10 12 3 
Number diagnosed before screening 
(excluded from following age data) 
5 1 0 0 
Number of babies with age at first 
appointment reported 
223 9 11 3 
Number seen ≤ 21days standard (% of 
known data) 
186 (83.0%) 7 (77.8%) 8 (72.7%) 3 (100%) 
All babies mean age at first appointment 19 16 20 20 
All babies median age at first appointment 19 16 19 19 
Age range at first appointment 10-46 days 14-39 days 15- 27 days 19-21 
days 
Number of babies with age at first 
appointment not reported 
13 0 1 0 
Inpatient  2 0 0 0 
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Figure 18: Age in days of CHT screen positive babies (not including preterm babies) 
detected on first and second sample at time of first appointment 1 April 2017 to 31 March 
2018, England only  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
 
CHT – screen positive preterm babies (born at less than 32 weeks) 
Data on CHT preterm babies will be further analysed in detail separately. 
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CHT results depending on use of national or local borderline cut-off level 
CHT is the only screening protocol in which a borderline result necessitates a second 
sample before a conclusive result can be achieved. The national borderline cut-off level 
is 10 mU/L. Some laboratories use a local cut-off level. 
 
Table 19: CHT borderline results depending on use of national or local cut-off level 1 
April 2017 to 31 March 2018 
  
Laboratory 
What TSH* cut-
off levels do you 
use to determine 
a positive screen 
for CHT (mU/L)? 
What TSH cut-off levels 
do you use to determine 
a borderline screen for 
CHT (mU/L)? 
Total number of 
CHT borderline 
results on the 
first sample 
using national 
TSH cut-off level 
(10-20 mU/L) 
Total number 
of CHT 
borderline 
results on the 
first sample 
using local 
TSH cut-off 
level 
Bristol 18 5.5 8 20 
Cambridge 18 (GSP) 9 (GSP) 23 32 
GOSH** 18 (GSP) 8 (GSP) 29 127 
Leeds 20 10 46 46 
Liverpool 20 5 26 217 
Manchester 20 8 69 149 
Newcastle 20 6 11 20 
Oxford 20 10 34 34 
Portsmouth 20 8 30 71 
SE Thames 20 10 (Q1- Q3) 
8 (Q4) 
55 55 
Sheffield 18 (GSP) 9 (GSP) 103 103 
SW Thames 20 10 until 01/01/18. 
8 from 01/12/17-31/03/18 
42 64 
West Midlands 20 10 15 15 
England total n/a n/a 507 855 
Northern Ireland 20 8 22 56 
Scotland 20 8 not completed not completed 
Wales  20 10 45 45 
Data source: Newborn screening laboratories  
*Thyroid stimulating hormone (TSH). 
**Note that GSP (Genetic Screening Processor) cut-offs are equivalent to national cut-offs.  
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Figure 19: CHT borderline results depending on use of national or local cut-off level 1 
April 2017 to 31 March 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
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CHT screen positive data 2007 to 2018 
Table 20: CHT screen positive data 2007 to 2018 
Laboratory Rate of CHT screen positives 2007 to 2018 
Rate per 10,000 
Bristol 6.62 
Cambridge 6.84 
GOSH 10.93 
Leeds 7.15 
Liverpool 10.60 
Manchester 7.83 
Newcastle 8.37 
Oxford 6.75 
Portsmouth 5.66 
SE Thames 5.86 
Sheffield 6.15 
SW Thames 6.26 
West Midlands 7.78 
England total 7.74 
Northern Ireland 7.26 
Scotland 5.08 
Wales  6.77 
UK total 7.51 
Data source: Newborn screening laboratories 
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PKU 
Description 
A baby in whom PKU is suspected should attend their first clinical appointment by 14 
days of age. 
  
Acceptable level 
100% by 14 days of age. 
 
Table 21: Timeliness of appointment and outcome for PKU screen positive babies 1 April 
2017 to 31 March 2018  
England Northern 
Ireland 
Scotland Wales 
Number of PKU screen positive babies  86 7 16 4 
Number clinically diagnosed before 
screening (excluded from following 
age data) 
5 0 0 0 
Number of babies with age at 
appointment reported 
55 7 0 4 
Number seen ≤ 14 days  
(% of known data) 
51 (92.7%) 7 (100%) n/a 3 (75%) 
All babies mean age at appointment 10 9 n/a 12 
All babies median age at appointment 10 9 n/a 11 
Age range at first appointment 7-21 days 7-11 days n/a 10-15 days 
Number of babies with age at 
appointment not reported 
26 0 16 0 
Data source: Newborn screening laboratories 
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Figure 20: Treatment outcome for PKU screen positive babies 1 April 2017 to 31 March 
2018, UK  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: age at first appointment for PKU screen positive babies 1 April 2017 to 31 
March 2018, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
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Table 22: PKU screen positive data 2007 to 2018 
Laboratory Rate of PKU screen positives 2007 to 2018 
Rate per 10,000 
Bristol 0.80 
Cambridge 1.77 
GOSH 0.90 
Leeds 1.23 
Liverpool 1.16 
Manchester 1.49 
Newcastle 1.39 
Oxford 0.89 
Portsmouth 0.79 
SE Thames 1.14 
Sheffield 1.56 
SW Thames 0.75 
West Midlands 0.92 
England total 1.11 
Northern Ireland 2.69 
Scotland 1.59 
Wales  1.70 
UK total 1.22 
Data source: Newborn screening laboratories 
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MCADD screen positive data 2017 to 2018 
Description 
A baby in whom MCADD is suspected should attend their first clinical appointment by:  
 
Acceptable level 
100% by 17 days of age.  
 
Achievable level 
100% by 14 days of age. 
 
Table 23: Timeliness of appointment and outcome for MCADD screen positive babies 1 
April 2017 to 31 March 2018  
England Northern 
Ireland 
Scotland Wales 
Number of MCADD screen positive babies  56 3 4 4 
Family history (early testing excluded from 
following age data) 
4 0 0 0 
Number of babies with age at appointment 
reported 
41 3 0 4 
Number seen ≤ 14 days  40 3 Not reported 4 
Number seen ≤ 17 days 41 3 Not reported 4 
All babies mean age at appointment 9 7 Not reported 10 
All babies median age at appointment 9 8 Not reported 10 
Age range at first appointment 7-15 days 6-8 days Not reported 10-11 
days 
Number of babies with age at appointment 
not reported 
11 0 4 0 
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Figure 22: Treatment outcome for MCADD screen positive babies, 1 April 2017 to 31 
March 2018, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
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Figure 23 UK: age at first appointment for MCADD screen positive babies 1 April 2017 to 
31 March 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data source: Newborn screening laboratories 
 
The biochemical data reported for MCADD was incomplete and therefore unable to map to the MCADD 2017/18 algorithm. 
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MCADD screen positive data 2008 to 2018 
Table 24: MCADD screen positive data 2008 to 2018 
Laboratory Rate of MCADD screen positives 2008 to 2017 
Rate per 10,000 
Bristol 0.82 
Cambridge 1.35 
GOSH 0.72 
Leeds 1.42 
Liverpool 1.03 
Manchester 1.16 
Newcastle 1.00 
Oxford 1.22 
Portsmouth 1.03 
SE Thames 0.73 
Sheffield 1.47 
SW Thames 0.82 
West Midlands 0.84 
England total 1.00 
Northern Ireland 1.17 
Scotland 0.38 
Wales  0.98 
UK total 0.97 
Data source: Newborn screening laboratories 
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MSUD, IVA, GA1 and HCU screen positive data 2017 to 2018 
Table 25: UK: Timeliness of appointment and outcome for MSUD, IVA, GA1 and HCU 
screen positive babies 1 April 2017 to 31 March 2018 
  MSUD IVA GA1 HCU 
Number of screen positive babies  10 14 6 7 
Family history (early testing) 0 0 1 1 
Number of babies with age at first 
appointment reported 
5 9 4 4 
Number seen ≤ 14 days  5 9 4 2 
Number seen ≤ 17 days2 5 9 4 3 
All babies median age at first 
appointment (in days) 
9 10 10 15 
Age range at first appointment (in days) 8-14  10-13 8-12 13-24  
Number of babies with age at first 
appointment not reported 
5 5 1 2 
Outcome (includes number diagnosed before screening) 
Confirmed  2 1 2 4 
Mild (IVA only)  n/a 1 n/a n/a 
Other disorder 0 0 1 0 
False positive  3 8 1 1 
Not reported 5 4 2 2 
Data source: Newborn screening laboratories 
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Figure 24. Outcomes for MSUD, IVA, GA1 and HCU, UK, 1 April 2017 to 31 March 2018 
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Standard 12a: Timeliness of results to 
parents (CCG responsibility at birth)   
Description 
The proportion of babies with a not suspected result for each of the conditions for whom 
a not suspected results letter was despatched directly to parents by the CHRD within 6 
weeks of birth. 
 
Acceptable threshold 
100% of babies with a not suspected result for each of the conditions for whom a not 
suspected results letter was despatched directly to parents by the CHRD within 6 weeks 
of birth. 
 
Table 26: Timeliness of results to parents, England 1 April 2017 to 31 March 2018 
Regional summary Numerator Denominator Performance 
England 458,947 468,844 97.9 
London 110,226 111,405 98.9 
Midlands & East 145,930 146,435 99.7 
North 87,789 88,979 98.7 
South 115,002 122,025 94.2 
 
Table 27: standard 12a, completeness of data, England 1 April 2017 to 31 March 2018 
Regional summary Number of non-
submissions 
Number with 
no data 
No. complete 
returns 
% complete 
returns 
England 36 6 165 82.1 
London 0 0 32 100.0 
Midlands & East 12 0 49 80.3 
North 19 6 39 67.2 
South 5 0 45 90.0 
 
Data source: CHRDs 
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Standard 12b: Timeliness of results to 
parents (movers in) 
Description 
The proportion of babies with a not suspected result for each of the conditions screened 
for whom a not suspected results letter was despatched directly to parents by the 
CHRD within 6 weeks of notification of movement in. 
 
Acceptable threshold  
100% of babies with a not suspected result for each of the conditions for whom a not 
suspected results letter was despatched directly to parents by the CHRD within 6 weeks 
of notification of movement in. 
 
Table 28: Timeliness of results to parents, movers in, England 1 April 2017 to  
31 March 2018 
Regional summary Numerator Denominator  Performance  
England 19,074 20,833 91.6 
London 6,380 7,060 90.4 
Midlands & East 7,629 8,175 93.3 
North   2,934 3,057 96.0 
South 2,131 2,541 83.9 
 
Table 29: Completeness of data, movers in, England 1 April 2017 to 31 March 2018 
Regional summary Number of non-
submissions 
Number with no 
data 
No. complete 
returns 
% complete 
returns 
England 37 53 117 56.5 
London 0 1 31 97.0 
Midlands & East 12 14 35 57.4 
North   19 17 28 43.8 
South 6 21 22 44.9 
 
Twenty-nine CHRDs completed the wrong template containing only standard 12a. 
Therefore, the data for this standard cannot be used for quality assurance as the data is 
inconsistent across areas.   
 
Completeness for standard 12 is poor. Work needs to be done in Midlands and East, 
North and South regions to improve completeness and data. The blood spot programme 
needs to work closely with SQAS in achieving a better data return and communicating 
the submission process widely.  
